Comparing two eye numbing gels for shots
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You need an anti-VEGF injection in one eye for a condition like wet macular degeneration or diabetic eye disease
- You have had at least 3 anti-VEGF injections in that eye before
- You have had fewer than 13 injections in the past year
- You are willing to follow the study schedule and return for checkups
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This study compares two ways to keep the eye open during injections for conditions like wet macular degeneration. It tests a new method using a cotton-tipped applicator instead of a speculum to see if it is less painful and just as safe.
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
Hear when a new Retinal Vein Occlusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.